Valneva SE Company Overview and Performance

Valneva SE is a French biotech company that specializes in the development of vaccines for infectious diseases. The company was founded in 2009 by Thomas Lingelbach.

Valneva SE is headquartered in Saint-Herblain, France. It has a strong presence in Europe and the US.

Valneva SE has a diverse portfolio of vaccine candidates, including those for diseases such as Lyme disease, COVID-19, and chikungunya.

Valneva SE is a company that specializes in developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs.

Their product portfolio includes vaccines against Japanese Encephalitis, Cholera, and Chikungunya. They also have a pipeline of vaccine candidates in development, including one for Lyme disease.

One of their notable products is IXIARO, a vaccine against Japanese Encephalitis that is approved in Europe, America, and Australia. Another product is DUKORAL, a vaccine against cholera and LT-ETEC that is approved in Europe, Canada, and Australia.

Valneva SE also has a vaccine called IXCHIQ, which is a live-attenuated, single-dose vaccine against the Chikungunya virus. This vaccine was approved in 2023 and is a significant milestone for the company.

A unique perspective: BAE Systems Australia

Here are some of the products and services offered by Valneva SE:

Their distribution services include providing distribution for third-party products, and they also have a vaccine development pipeline with targeted development programs using proprietary technology platforms.

Valneva SE is actively involved in clinical trials, which are a crucial part of determining the company's go-to-market proposition. This involves gaining insight into the company's clinical operations, recruitment, and trial strategy.

Valneva SE has a unit that's receiving a significant investment of $30 million from BioPharma Credit, which will likely support the company's clinical trials and research efforts. This investment is a vote of confidence in Valneva SE's work.

Valneva SE has recently lowered its financial forecasts for 2025, which may indicate a shift in the company's priorities or a re-evaluation of its goals.

Clinical trials are a crucial step in the development of new treatments and vaccines. Valneva SE's go-to-market proposition involves conducting clinical trials to determine the efficacy and safety of their products.

Valneva SE focuses on clinical operations, recruitment, and trial strategy to ensure the success of their clinical trials.

Valneva's commitment to combating infectious diseases worldwide is evident in their portfolio choices. They focus on vaccines for specific diseases like Lyme disease, chikungunya, and Zika.

This approach demonstrates a clear strategy centered on prevention and addressing specific health threats. Their mission is to protect populations through vaccination, aiming for tangible improvements in global health outcomes.

Valneva's focus on public health impact resonates with their goal of achieving financial sustainability alongside global health improvements. By prioritizing vaccines for specific diseases, they can make a meaningful difference in the lives of people worldwide.

Valneva's partnership with Pfizer is a significant milestone in the development of the Lyme disease vaccine candidate VLA15. This collaboration, initiated in 2019, brings together Valneva's expertise with Pfizer's resources for late-stage development and global commercialization.

Pfizer's involvement significantly de-risks the program for Valneva, allowing them to focus on the next steps in the development process.

Discover more: Pfizer UK

In the realm of biotechnology and medical research, Valneva SE is making significant strides. They've recently secured a $30 million investment from BioPharma Credit for their unit, demonstrating confidence in their research and development efforts.

This investment is a testament to the potential of Valneva's work in combating infectious diseases worldwide. Their focus on prevention and addressing specific health threats is a key aspect of their strategy.

Valneva's portfolio choices, such as vaccines for Lyme disease, chikungunya, and Zika, reflect their commitment to protecting populations through vaccination. Their mission is clear: to make tangible improvements in global health outcomes while ensuring financial sustainability.

Here's a brief overview of their recent financial updates:

These updates highlight the company's efforts to adapt to changing circumstances and stay on track with their goals.

Valneva SE's financial performance has been a highlight of recent years. The company demonstrated significant revenue growth in fiscal year 2024, primarily fueled by the initial sales ramp-up of its Chikungunya vaccine, IXCHIQ.

Total revenues for 2024 reached approximately €185 million, a notable increase from previous years. This growth was driven by the commercial execution of its specialized vaccine portfolio.

Product sales gross margin hovered around 58%, reflecting the value of its specialized portfolio but also the costs associated with new product launches. Research and Development expenses remained substantial, estimated at around €90 million.

This high R&D spend resulted in an anticipated operating loss for the full year 2024, although potentially narrower than in previous years. This indicates progress towards profitability driven by commercial execution.

Valneva SE's financial performance is heavily influenced by its specialized vaccine market. Key cost components include R&D expenditures, clinical trial costs, and vaccine manufacturing (cost of goods sold).

Revenue generation relies heavily on successful commercial launches and market penetration of new vaccines. This makes strategic partnerships crucial for funding late-stage development and accessing broader commercial infrastructure.

Here are the key financial metrics for Valneva SE in 2024:

Valneva SE operates as a specialty vaccine company, focusing on prophylactic vaccines for infectious diseases with significant unmet medical needs. Its future outlook hinges significantly on the successful commercialization of its newly approved chikungunya vaccine, IXCHIQ, and the progression of its Lyme disease vaccine candidate, VLA15, currently in Phase 3 trials with partner Pfizer.

Valneva holds a distinct position as a mid-sized player focused on innovation within specific, often overlooked, vaccine markets like chikungunya and Japanese encephalitis. This focus allows for deeper expertise but also carries concentration risk.

The company's success with IXIARO and the approval of IXCHIQ solidify its role as a key innovator in travel and emerging infectious disease vaccines. Its ability to execute its commercial strategy for IXCHIQ and advance the Lyme program with Pfizer will be critical determinants of its industry standing moving towards 2025.

Here are some key market position and outlook facts about Valneva SE:

Valneva's path forward involves capitalizing on unique market openings while mitigating inherent industry risks. Successful global launch and market penetration of IXCHIQ could potentially generate peak sales estimated over €500 million annually.

You might like: Basf Se Market Cap

Valneva SE's leadership team is led by Thomas Lingelbach, who serves as the Chief Executive Officer (CEO) and has been in the position since the company's founding.

The company's Management Board, which guides its strategic direction and operations, includes Peter Bühler as the Chief Financial Officer (CFO) and Juan Carlos Jaramillo, MD, as the Chief Medical Officer (CMO).

Franck Grimaud serves as the President and Chief Business Officer, playing a key role in the company's business strategy. Anne-Laure Sanguinetti chairs the Supervisory Board, overseeing the company's governance.

Here is a list of key members of the Supervisory Board:

The founding team members of Valneva played a crucial role in shaping the company's leadership and governance. Thomas Lingelbach, previously CEO of Intercell, became President and CEO of Valneva.

Key figures included Thomas Lingelbach and Franck Grimaud.

For more insights, see: Thomas Green & Son

Valneva SE has a strong leadership team that guides the company's strategic direction and operations. Thomas Lingelbach serves as the Chief Executive Officer (CEO), while Peter Bühler is the Chief Financial Officer (CFO).

The company's leadership team is led by Thomas Lingelbach, who has been in the role since the company's inception. He previously served as CEO of Intercell.

Franck Grimaud, previously CEO of Vivalis, serves as the President and Chief Business Officer. His experience in the industry has been invaluable in shaping Valneva's business strategy.

The company's Supervisory Board is chaired by Anne-Laure Sanguinetti. The Board oversees the company's operations and provides strategic guidance.

Here is a list of the key members of Valneva's leadership team:

The company's Board of Directors is composed of experienced individuals with diverse backgrounds and expertise. The current members include Thomas Lingelbach, James Sulat, Anne-Marie Graffin, Maïlys Ferrère, Jim Connolly, Kathrin Jansen, Danièle Guyot-Caparros, and Gerd Zettlmeissl.

The Executive Committee is responsible for overseeing the company's day-to-day operations. The current members include Thomas Lingelbach (CEO), Peter Bühler (CFO), Vincent Dequenne (COO), Juan Carlos Jaramillo (CTO), and Joshua Drumm (Investor Relations Contact).

Valneva SE's guiding principles are the foundation of their leadership and governance approach. These principles are rooted in their mission to contribute significantly to global public health through innovation in vaccine technology.

At the heart of Valneva SE's guiding principles is a commitment to innovation. They drive vaccine development through scientific excellence, which is a testament to their dedication to making a meaningful impact in the lives of people around the world.

One of the key principles that guides Valneva SE's research, development, and commercial activities is their commitment to addressing unmet medical needs in infectious diseases. This is a critical aspect of their public health goals, and it's clear that they're dedicated to making a difference.

Valneva SE's collaboration with partners globally is another key principle that advances their vaccine solutions. By working together, they're able to share knowledge, expertise, and resources, which ultimately leads to better outcomes for patients.

Suggestion: Basf Se Key Debates

In addition to innovation, commitment, and collaboration, Valneva SE also upholds high ethical standards in all their operations. This is reflected in their principle of integrity, which is essential for building trust with their partners, customers, and the broader community.

Here are the five guiding principles that Valneva SE operates by:

By living out these principles, Valneva SE is able to create a culture that values employees and teamwork, which is essential for driving innovation and making a meaningful impact in the world.

Valneva SE operates as a publicly traded company with a diverse ownership base. This structure is composed primarily of institutional investors, strategic partners, and the public market.

Institutional investors hold a significant portion of the company's shares, approximately 58% according to the latest data. This includes mutual funds, pension funds, and asset managers holding substantial positions.

Strategic partners, such as Pfizer, also play a notable role in the company's ownership structure. Pfizer's equity investment in 2022 related to the Lyme disease vaccine partnership accounts for around 8.1% of the company's shares.

Here's a breakdown of the company's largest shareholders:

Valneva's initial capitalization was based on the combined assets and market valuation of Intercell and Vivalis at the time of the merger.

This unique approach to funding is a result of Valneva being a merger of two existing publicly listed companies.

The traditional startup funding route wasn't taken, allowing Valneva to skip the usual fundraising process.

This approach likely saved Valneva time and resources that would have been spent on securing investments.

Valneva SE operates as a publicly traded company with a diverse ownership base.

The company's shares are primarily held by institutional investors, strategic partners, and the public market. This structure influences its governance and strategic direction.

Institutional investors hold approximately 58% of the company's shares. This includes mutual funds, pension funds, and asset managers holding significant positions.

Strategic partners, such as Pfizer, hold around 8.1% of the shares. This reflects the equity investment made by Pfizer in 2022 related to the Lyme disease vaccine partnership.

Additional reading: Antin Infrastructure Partners

Significant historical holders, including Bpifrance and Groupe Grimaud, hold around 7% of the shares. However, their percentages may fluctuate.

Retail investors and other entities hold around 26.9% of the shares.

Here's a breakdown of the top shareholders:

The stock code FR0004056851 is listed on the Euronext Paris stock market. It's currently trading at 4.768.

This stock code is associated with a 5-day change of +1.02%. That's a relatively modest increase over the past week.

You can find the current trading time in Eastern Daylight Time (EDT) for this stock code, which is 04:09:41 on October 9, 2025.

The stock has experienced significant fluctuations in value over time, with a 1st January change of -4.80% and a 1st January change of +119.98% from an unspecified earlier date.

Valneva SE is a biotech company that has been making waves in the industry.

Valneva SE is headquartered in France, specifically in Saint-Herblain, a suburb of Nantes.

The company's main focus is on developing vaccines for infectious diseases, with a particular emphasis on diseases that affect the elderly and those with weakened immune systems.

Valneva SE has a significant presence in the UK, with a manufacturing facility in Livingston, Scotland, which is a major hub for the company's vaccine production.

Let's take a look at the historical data for the past 5 days. The Der. (derivative) value on October 3 was 4,976, which is a decrease of -0.40% from the previous day.

The volume of trades on October 3 was 963,873.

Here's a breakdown of the Der. values and their corresponding variations for each day:

The overall variation over the past 5 days is a decrease of -4.84%.

I've been keeping an eye on the latest messages on the VALNEVA forum, and it's been quite interesting. The recent rebound on 3.5 has helped close the gap between 4.15 and 4.9, a significant achievement.

The current market situation for VALNEVA is a bit complex, but let's break it down. The consolidation has stopped at 4.71, just short of the gap between 4.6 and 4.9.

If you're following VALNEVA, you might want to take a look at this list of similar companies: